Accordingly, the treatment of lapatinib-resistant breast cancer cell lines with 4SC-202 led to an increase in PHLDA1 levels (Figure 4A) and elevated H3K27ac at the PHLDA1 locus (Figure S4C). This evidence concerns the gene PHLDA1 and breast carcinoma.